Evaluación de la capacidad que tienen los niveles de ácido desoxirribonucleico libre circulante mitocondrial y nuclear urinario para discriminar muestras de sujetos con nefritis lúpica

datacite.rightshttp://purl.org/coar/access_right/c_16ecspa
dc.contributor.advisorNavarro, Elkin
dc.contributor.advisorNavarro, Roberto
dc.contributor.authorMárquez Escobar, Olga Cecilia
dc.date.accessioned2022-08-01T16:07:18Z
dc.date.available2022-08-01T16:07:18Z
dc.date.issued2022
dc.description.abstractEl lupus eritematoso sistémico (LES), es una enfermedad autoinmune, proclive a una presentación clínica heterogénea que debuta de manera silente en casos de nefritis lúpica activa (NLA), lo cual es mandatorio de una biopsia renal percutánea con consecuentes eventos adversos. Objetivo: Evaluar la capacidad que tienen los niveles de ADN libre circulante mitocondrial y nuclear urinario (uADN-lc) para discriminar muestras de sujetos con nefritis lúpica activa (NLA). Sujetos y Métodos: Se tomaron muestras de orina de (74) sujetos, (25) con LES sin compromiso renal, (12) con NLA (12) con NLR y (25) Controles sanos. Se realizó una reacción en cadena de la polimerasa en tiempo real (qPCR) para la cuantificación de las moléculas de ácido desoxirribonucleico libre circulante (ADN-lc), mediante el empleo de genes constitutivos ND1 (mitocondrial) y GAPDH (nuclear), a posteriori de su extracción urinaria (uADN-lc), mediante el Kit Comercial de Aislamiento con Perlas Magnéticas (Applied Biosystems), y la determinación de su concentración con espectrofotómetro (Nanodrop One 2000 de Thermo Scientific ®) y analizador de imágenes.spa
dc.description.abstractSystemic lupus erythematous (SLE) is an autoimmune disease, prone to a heterogeneous clinical presentation that debuts silently in cases of active lupus nephritis (ALN), which is mandatory for a percutaneous renal biopsy with consequent adverse events. Objective: To evaluate the ability of mitochondrial and nuclear urinary cell-free DNA (cf-uDNA) levels to discriminate samples from subjects with active lupus nephritis (ALN). Subjects and Methods: Urine samples were taken from (74) subjects, (25) with SLE without kidney failure, (12) with (ALN), (12) with (RLN) and (25) Healthy Controls. A quantitative real-time polymerase chain reaction (Q-PCR) was performed for cell-free deoxyribonucleic acid molecule quantification (cf-DNA), using constitutive genes ND1 (mitochondrial) and GAPDH (nuclear), after their urinary extraction (cf-uDNA), by means of the Commercial Isolation Kit with Magnetic Pearls (Applied Biosystems), and its concentration measurement with spectrophotometer (Nanodrop One 2000 de Thermo Scientific ®) and image analyzer.eng
dc.format.mimetypepdfspa
dc.identifier.urihttps://hdl.handle.net/20.500.12442/10436
dc.language.isospaspa
dc.publisherEdiciones Universidad Simón Bolívarspa
dc.publisherFacultad de Ciencias Básicas y Biomédicasspa
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacionaleng
dc.rights.accessrightsinfo:eu-repo/semantics/restrictedAccessspa
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectComplejos inmunesspa
dc.subjectConcentración de ácido desoxirribonucleico libre circulante urinario (uADN-lc)spa
dc.subjectGAPDHspa
dc.subjectSLEDAIspa
dc.subjectSLICCspa
dc.subjectND1spa
dc.subjectNefritis lúpica activa (NLA)spa
dc.subjectConcentration of urinary circulating free deoxyribonucleic acid (uDNA-lc)eng
dc.subjectActive lupus nephritis (ANL)eng
dc.titleEvaluación de la capacidad que tienen los niveles de ácido desoxirribonucleico libre circulante mitocondrial y nuclear urinario para discriminar muestras de sujetos con nefritis lúpicaspa
dc.title.translatedAssessment of the ability of mitochondrial and nuclear urinary cell free circulating deoxyribonucleic acid levels to discriminate samples from subjects with Lupus Nephritiseng
dc.type.driverinfo:eu-repo/semantics/masterThesisspa
dc.type.spaTrabajo de grado másterspa
dcterms.referencesOparina N, Martínez-Bueno M, Alarcón-Riquelme ME. An update on the genetics of systemic lupus erythematosus. Current Opinion in Rheumatology. 2019; 31(6):659–68.eng
dcterms.referencesVaillant AAJ, Goyal A, Bansal P, Varacallo M. Systemic Lupus Erythematosus (SLE) - StatPearls - NCBI Bookshelf. StatPearls [Internet]. 2020.eng
dcterms.referencesMusso CG, Terrasa S, Ciocchini M, Gonzalez-Torres H, Aroca-Martinez G. Looking for a better definition and diagnostic strategy for acute kidney injury: A new proposal. Vol. 117, Archivos Argentinos de Pediatria. Sociedad Argentina de Pediatria; 2019. p. 4–5.eng
dcterms.referencesPan L, Lu MP, Wang JH, Xu M, Yang SR. Immunological pathogenesis and treatment of systemic lupus erythematosus. World Journal of Pediatrics. 2020; 16(1):19–30.eng
dcterms.referencesJustiz Vaillant AA, Sabir Sarah, Jan Arif. Physiology, Immune Response - StatPearls - NCBI Bookshelf. 2020.eng
dcterms.referencesPons-Estel BA, Bonfa E, Soriano ER, Cardiel MH, Izcovich A, Popoff F, et al. First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)-Pan-American League of Associations of Rheumatology (PAN. Annals of the Rheumatic Diseases. 2018; 77(11):1549–57.eng
dcterms.referencesAhmadpoor P, Dalili N, Rostami M. An update on pathogenesis of systemic lupus erythematosus. Iranian journal of kidney diseases. 2014 May; 8(3):171–84.eng
dcterms.referencesAlonso L, Naranjo G, María G, Duque V, Uribe OU, Alberto L, et al. Nefropatía lúpica: presentación clínica, clasificación y tratamiento. Revista Colombiana de Reumatologìa. 2006; 13(4):307-33.spa
dcterms.referencesLatinoamérica DE, Depine SÁ, Aroca Martínez G. DESAFIANDO A LA INEQUIDAD.spa
dcterms.referencesSánchez E, Gómez LM, Lopez-Nevot MA, González-Gay MA, Sabio JM, Ortego-Centeno N, et al. Evidence of association of macrophage migration inhibitory factor gene polymorphisms with systemic lupus erythematosus. Genes and Immunity. 2006;7(5):433–6.eng
dcterms.referencesHernández FR. Biopsia renal. Acta Pediátrica de México. 2009; 30(1):36–53.spa
dcterms.referencesPombas B, Rodríguez E, Sánchez J, Radosevic A, Gimeno J, Busto M, et al. Risk factors associated with major complications after ultrasound-guided percutaneous renal biopsy of native kidneys. Kidney and Blood Pressure Research. 2020; 45(1):122–30.eng
dcterms.referencesPerez-Hernandez J, Martinez-Arroyo O, Ortega A, Galera M, Solis-Salguero MA, Chaves FJ, et al. Urinary exosomal miR-146a as a marker of albuminuria, activity changes and disease flares in lupus nephritis. Journal of Nephrology. 2020;(0123456789).eng
dcterms.referencesHusi H, Human C. Molecular determinants of acute kidney injury. Journal of Injury and Violence Research. 2014; 7(2):75-86.eng
dcterms.referencesPacheco-Lugo L, Sáenz-García J, Navarro Quiroz E, González Torres H, Fang L, Díaz-Olmos Y, et al. Plasma cytokines as potential biomarkers of kidney damage in patients with systemic lupus erythematosus. Lupus. 2019 Jan 1; 28(1):34–43.eng
dcterms.referencesJohnson SR, Brinks R, Costenbader KH, Daikh D, Mosca M, Ramsey-Goldman R, et al. Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities. Annals of the Rheumatic Diseases. 2020; 1-7.eng
dcterms.referencesTruszewska A, Wirkowska A, Gala K, Truszewski P, Krzemień-Ojak Ł, Perkowska-Ptasińska A, et al. Cell-free DNA profiling in patients with lupus nephritis. Lupus. 2020; 0(0):1–14.eng
dcterms.referencesDing Y, Yu X, Wu L, Tan Y, Qu Z, Yu F. The Spectrum of C4d Deposition in Renal Biopsies of Lupus Nephritis Patients. Vol. 12, Frontiers in Immunology. 2021.eng
dcterms.referencesRamos-Casals M, Campoamor MT, Chamorro A, Salvador G, Segura S, Botero JC, et al. Hypocomplementemia in systemic lupus erythematosus and primary antiphospholipid syndrome: prevalence and clinical significance in 667 patients. Lupus. 2004 Oct 2; 13(10):777–83.eng
dcterms.referencesLópez-Gómez JM, Rivera F. Renal biopsy findings in acute renal failure in the cohort of patients in the Spanish registry of glomerulonephritis. Clinical Journal of the American Society of Nephrology. 2008; 3(3):674–81.eng
dcterms.referencesLeuchten N, Hoyer A, Brinks R, Schoels M, Schneider M, Smolen J, et al. Performance of Antinuclear Antibodies for Classifying Systemic Lupus Erythematosus: A Systematic Literature Review and Meta-Regression of Diagnostic Data. Arthritis Care and Research. 2018; 70(3):428–38.eng
dcterms.referencesSagheb MM, Namazi S, Geramizadeh B, Karimzadeh A, Oghazian MB, Karimzadeh I. Serum cystatin C as a marker of renal function in critically Ill patients with normal serum creatinine. Nephro-Urology Monthly. 2014; 6(2).eng
dcterms.referencesPathogens S. What is damaging the kidney in lupus nephritis? Nature reviews Rheumatology. 2016; 1848(3):3047–54.eng
dcterms.referencesOreskovic A, Brault ND, Panpradist N, Lai JJ, Lutz BR. Analytical Comparison of Methods for Extraction of Short Cell-Free DNA from Urine. Journal of Molecular Diagnostics. 2019; 21(6):1067–78.eng
dcterms.referencesMoroni G, Quaglini S, Radice A, Trezzi B, Raffiotta F, Messa P, et al. The value of a panel of autoantibodies for predicting the activity of lupus nephritis at time of renal biopsy. Journal of Immunology Research. 2015; 2015.eng
dcterms.referencesPotter B. The history of the disease called lupus. Journal of the History of Medicine and Allied Sciences. 1993; 48(1):80–90.eng
dcterms.referencesPisetsky DS, Lipsky PE. New insights into the role of antinuclear antibodies in systemic lupus erythematosus. Nature Reviews Rheumatology. 2020;16(10):565–79.eng
dcterms.referencesFortuna G, Brennan MT. Systemic lupus erythematosus. Epidemiology, pathophysiology, manifestations, and management. Dental Clinics of North America. 2013; 57(4):631–55.eng
dcterms.referencesAlarcón GS, McGwin G, Petri M, Reveille JD, Ramsey-Goldman R, Kimberly RP, et al. Baseline characteristics of a multiethnic lupus cohort: PROFILE. Lupus. 2002; 11(2):95–101.eng
dcterms.referencesJavierre BM, Hernando H, Ballestar E. Environmental triggers and epigenetic deregulation in autoimmune disease. Discovery medicine. 2011 Dec; 12(67):535–45.eng
dcterms.referencesBarber MRW, Drenkard C, Falasinnu T, Hoi A, Mak A, Kow NY, et al. Global epidemiology of systemic lupus erythematosus. Nature Reviews Rheumatology. 2021; 17(9):515–32.eng
dcterms.referencesGoulielmos GN, Zervou MI, Vazgiourakis VM, Ghodke-Puranik Y, Garyfallos A, Niewold TB. The genetics and molecular pathogenesis of systemic lupus erythematosus (SLE) in populations of different ancestry. Gene. 2018; 668(May):59–72.eng
dcterms.referencesNielsen CT. Circulating microparticles in systemic lupus erythematosus. Danish Medical Journal. 2012; 59(11):1–34.eng
dcterms.referencesJavinani A, Ashraf-Ganjouei A, Aslani S, Jamshidi A, Mahmoudi M. Exploring the etiopathogenesis of systemic lupus erythematosus: a genetic perspective. Immunogenetics. 2019; 71(4):283–97.eng
dcterms.referencesZhan Y, Guo Y, Lu Q. Aberrant Epigenetic Regulation in the Pathogenesis of Systemic Lupus Erythematosus and Its Implication in Precision Medicine. Cytogenetic and Genome Research. 2016; 149(3):141–55.eng
dcterms.referencesRodsaward P, Chottawornsak N, Suwanchote S, Rachayon M, Deekajorndech T, Wright HL, et al. The clinical significance of antinuclear antibodies and specific autoantibodies in juvenile and adult systemic lupus erythematosus patients. Asian Pacific journal of allergy and immunology. 2021; 39(4).eng
dcterms.referencesAvaniss-Aghajani E, Berzon S, Sarkissian A. Clinical value of multiplexed bead-based immunoassays for detection of autoantibodies to nuclear antigens. Clinical and Vaccine Immunology. 2007;1 4(5):505-9.eng
dcterms.referencesMortensen ES, Fenton KA, Rekvig OP. Lupus nephritis: The central role of nucleosomes revealed. American Journal of Pathology. 2008; 172(2):275–83.eng
dcterms.referencesGoropevšek A, Holcar M, Avčin T. The Role of STAT Signaling Pathways in the Pathogenesis of Systemic Lupus Erythematosus. Clinical Reviews in Allergy and Immunology. 2017; 52(2):164–81.eng
dcterms.referencesVahedi G, Takahashi H, Nakayamada S, Sun HW, Sartorelli V, Kanno Y, et al. STATs shape the active enhancer landscape of T cell populations. Cell. 2012; 151(5):981–93.eng
dcterms.referencesHo J, Tangri N, Komenda P, Kaushal A, Sood M, Brar R, et al. Urinary, Plasma, and Serum Biomarkers’ Utility for Predicting Acute Kidney Injury Associated With Cardiac Surgery in Adults: A Meta-analysis. American Journal of Kidney Diseases. 2015; 66(6):993–1005.eng
dcterms.referencesBroza YY, Zhou X, Yuan M, Qu D, Zheng Y, Vishinkin R, et al. Disease Detection with Molecular Biomarkers: From Chemistry of Body Fluids to Nature-Inspired Chemical Sensors. Chemical Reviews. 2019; 119(22):11761–817.eng
dcterms.referencesKazumitsu Nawata MK. Imp. Global Facts_ About Kidney Disease - The National Kidney Foundation. Health, December 8, 2017; 2017. p. Vol.9 No.13.eng
dcterms.referencesBombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, Austin A, et al. Derivation of the sledai. A disease activity index for lupus patients. Arthritis & Rheumatism. 1992; 35(6):630–40.eng
dcterms.referencesMargulis L. Genetic and evolutionary consequences of symbiosis. Experimental Parasitology. 1976; 39(2):277–349.eng
dcterms.referencesDye JR, Ullal AJ, Pisetsky DS. The Role of Microparticles in the Pathogenesis of Rheumatoid Arthritis and Systemic Lupus Erythematosus. Vol. 78, Scandinavian Journal of Immunology. 2013. p. 140–8.eng
dcterms.referencesKavanaugh A, Tomar R, Reveille J, Solomon DH, Homburger HA. Guidelines for clinical use of the antinuclear antibody test and tests for specific autoantibodies to nuclear antigens. American College of Pathologists. Arch Pathol Lab Med. 2000;124: 71–81.eng
dcterms.referencesChang A, Clark MR, Ko K. Cellular aspects of the pathogenesis of lupus nephritis. Vol. 33, Current Opinion in Rheumatology. 2021. p. 197–204.eng
dcterms.referencesAronson JK, Ferner RE. Biomarkers—a general review. Current Protocols in Pharmacology. 2017; 2017(March):9.23.1-9.23.17.eng
dcterms.referencesGil Hernández F. El papel de los biomarcadores en Toxicología Humana. Revista de Toxicología. 2000; 17(1):19–26.spa
dcterms.referencesHosni ND, Anauate AC, Boim MA. Reference genes for mesangial cell and podocyte (qPCR) gene expression studies under high-glucose and renin-angiotensin-system blocker conditions. Vol. 16, PLoS ONE. 2021.eng
dcterms.referencesColell A, Green DR, Ricci JE. Novel roles for GAPDH in cell death and carcinogenesis. Cell Death and Differentiation. 2009; 16(12):1573–81.eng
dcterms.referencesStoll T, Seifert B, Isenberg DA. SLICC/ACR damage index is valid, and renal and pulmonary organ scores are predictors of severe outcome in patients with systemic lupus erythematosus. British Journal of Rheumatology. 1996; 35(3):248–54.eng
dcterms.referencesGladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis and Rheumatism. 1996; 39(3):363–9.eng
dcterms.referencesAringer M. Lupus Eritematoso Sistémico Criterios De Clasificación Eular/Acr 2019. American College of Rheumatology. 2019; 78(11):1151.spa
dcterms.referencesFanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, et al. 2019 Update of the EULAR recommendations for the management of systemic lupus erythematosus. Vol. 78, Annals of the Rheumatic Diseases. 2019. p. 736–45.eng
dcterms.referencesAugustus E, van Casteren K, Sorber L, van Dam P, Roeyen G, Peeters M, et al. The art of obtaining a high yield of cell-free DNA from urine. PLoS ONE. 2020; 15(4):1-22.eng
dcterms.referencesBajema IM, Wilhelmus S, Alpers CE, Bruijn JA, Colvin RB, Cook HT, et al. Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney International. 2018; 93(4):789-96.eng
dcterms.referencesFu L, Wang YG. Robust regression with asymmetric loss functions. Statistical Methods in Medical Research. 2021; 30(8):1800-15.eng
dcterms.referencesThermo Scientific. NanoDrop 2000 / 2000c Spectrophotometer. Thermo scientific inc. 2000; 97.eng
dcterms.referencesMix M, Gels E gel GP, Mixes M. ∤ ∤ 0.2.eng
dcterms.referencesArnaud CH. Thermo fisher scientific. Vol. 84, Chemical and Engineering News. 2006. p. 11–5.eng
dcterms.referencesBikbov B, Purcell CA, Levey AS, Smith M, Abdoli A, Abebe M, et al. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet. 2020; 395(10225):709–33.eng
dcterms.references
dcterms.referencesAroca-Martínez GJ, Mendoza-Jaimes J, Gonzalez-Torres HJ, Dominguez-Vargas A, Martinez-Bayona Á, Navarro-Quiroz E, et al. Consecutive renal biopsy in a cohort of patients with lupus nephritis of the Colombian caribbean. Journal of Nephropathology. 2018; 7(4):233–40.eng
dcterms.referencesProgramme EM, Commission T. Standardisation of pre-analytical and analytical procedures for in vitro diagnostics in personalised medicine.: 1-2.eng
dcterms.referencesWagner JT, Kim HJ, Johnson-Camacho KC, Kelley T, Newell LF, Spellman PT, et al. Diurnal stability of cell-free DNA and cell-free RNA in human plasma samples. Vol. 10, Scientific Reports. 2020.eng
dcterms.referencesUeda BR, Shiku H, Pfreundschuh M, Takahashi T, Li LTC, Whitmore WF, et al. CELL SURFACE ANTIGENS OF HUMAN RENAL C A N C E R D E F I N E D BY A U T O L O G O U S T Y P I N G *. 1979; 150(September):564–79.eng
dcterms.referencesF YDRCJW. Distinct patterns and behavioural. World J Urolo; 2013. p. 21–9.eng
dcterms.referencesSaetun P, Semangoen T, Thongboonkerd V. Characterizations of urinary sediments precipitated after freezing and their effects on urinary protein and chemical analyses. Vol. 296, American Journal of Physiology - Renal Physiology. 2009.eng
dcterms.referencesTouma Z, Urowitz MB, Gladman DD. Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index-50 Website. Journal of Rheumatology. 2013; 40(5):733.eng
dcterms.referencesQuintana G, Coral-Alvarado P, Aroca G, Patarroyo PM, Chalem P, Iglesias-Gamarra A, et al. Single anti-P ribosomal antibodies are not associated with lupus nephritis in patients suffering from active systemic lupus erythematosus. Autoimmunity Reviews. 2010 Sep; 9(11):750-5.eng
dcterms.referencesFernández D, Rincon-Riaño DN, Bernal-Macías S, Rosselli D. Prevalencia y características demográficas del Lupus Eritematoso Sistémico, Miopatía Inflamatoria, Osteoporosis, Polimialgia Reumática, Síndrome Sjögren y Vasculitis en Colombia Burden of disease View project ANTI-DFS70 ANTIBODY View project. Available from: https://www.researchgate.net/publication/318967596.spa
dcterms.referencesNavarro-Quiroz E, Pacheco-Lugo L, Lorenzi H, Díaz-Olmos Y, Almendrales L, Rico E, et al. High-throughput sequencing reveals circulating miRNAs as potential biomarkers of kidney damage in patients with systemic lupus erythematosus. PLoS ONE. 2016 Nov 1; 11(11).eng
dcterms.referencesHsu B, Sherina V, McCall MN. Autoregressive modeling and diagnostics for (qPCR) amplification. Bioinformatics. 2020; 36(22–23):5386-91.eng
dcterms.referencesMalik AN, Czajka A. Is mitochondrial DNA content a potential biomarker of mitochondrial dysfunction? Mitochondrion. 2013 Sep; 13(5):481-92.eng
dcterms.referencesBerensmeier S. Magnetic particles for the separation and purification of nucleic acids. Vol. 73, Applied Microbiology and Biotechnology. 2006. p. 495–504.eng
dcterms.referencesNeuberger EWI, Brahmer A, Ehlert T, Kluge K, Philippi KFA, Boedecker SC, et al. Validating quantitative PCR assays for cfDNA detection without DNA extraction in exercising SLE patients. Scientific Reports. 2021; 11(1):1-11.eng
dcterms.referencesLapin M, Oltedal S, Tjensvoll K, Buhl T, Smaaland R, Garresori H, et al. Fragment size and level of cell-free DNA provide prognostic information in patients with advanced pancreatic cancer. Journal of Translational Medicine. 2018; 16(1):1-10.eng
dcterms.referencesHajian-Tilaki K. Receiver operating characteristic (ROC) curve analysis for medical diagnostic test evaluation. Caspian Journal of Internal Medicine. 2013; 4(2):627-35.eng
dcterms.referencesParr RL, Martin LH. Mitochondrial and nuclear genomics and the emergence of personalized medicine. Human Genomics. 2012; 6(1):1-8.eng
dcterms.referencesMa H, Bell KN, Loker RN. (qPCR) and qRT-PCR analysis: Regulatory points to consider when conducting biodistribution and vector shedding studies. Vol. 20, Molecular Therapy - Methods and Clinical Development. Cell Press; 2021. p. 152-68.eng
dcterms.referencesWang XS, Zhao MQ, Zhang L, Kong DJ, Ding XZ, Hu XC, Yang JQ GS. OTT-86908-urine-micrornas-as-biomarkers-for-bladder-cancer--a-diagnost _ Enhanced Reader. Am J Transl Res.; 2018. p. 1935-48.eng
dcterms.referencesChapman JR, Waldenström J. With reference to reference genes: A systematic review of endogenous controls in gene expression studies. PLoS ONE. 2015; 10(11):1-18.eng
dcterms.referencesTesis para obtener el grado de Doctor en Investigación y Docencia.spa
dcterms.referencesBerensmeier S. Magnetic particles for the separation and purification of nucleic acids. Vol. 73, Applied Microbiology and Biotechnology. 2006. p. 495-504.eng
dcterms.referencesPonti G, Maccaferri M, Manfredini M, Kaleci S, Mandrioli M, Pellacani G, et al. The value of fluorimetry (Qubit) and spectrophotometry (NanoDrop) in the quantification of cell-free DNA (cfDNA) in malignant melanoma and prostate cancer patients. Clinica Chimica Acta. 2018 Apr 1; 479: 14-9.eng
dcterms.referencesCaitlin M. Stewart, Prachi D Kothari, Florent Moulier, Richard Mair, Saira Somnay RB. The value of cell‐free DNA for molecular pathology _ Enhanced Reader. New York;eng
dcterms.referencesPatricia Valda Toro, Bracha Erlanger BHP. Comparison of Cell Stabilizing Blood Collection Tubes for Circulating Plasma Tumor DNA. Sidney; 2015. p. 1–15.eng
dcterms.referencesLiu B, Liu Y, Pan X, Li M, Yang S, Li SC. DNA methylation markers for pan-cancer prediction by deep learning. Genes. 2019; 10(10).eng
oaire.versioninfo:eu-repo/semantics/acceptedVersionspa
sb.programaMaestría en Genéticaspa
sb.sedeSede Barranquillaspa

Archivos

Bloque original
Mostrando 1 - 2 de 2
Cargando...
Miniatura
Nombre:
PDF_Resumen.pdf
Tamaño:
291.63 KB
Formato:
Adobe Portable Document Format
No hay miniatura disponible
Nombre:
PDF.pdf
Tamaño:
1.82 MB
Formato:
Adobe Portable Document Format

Colecciones